Cognitive dysfunction in elderly patients with depression based on chronic brain ischemia: vortioxetine (Brintellix) experience

Abstract

The effect of Vortioxetine (Brintellix) on the condition of cognitive functions and depression symptoms has been studied on a small population of middle aged and elderly patients with depression developed on the background of chronical brain ischemia. Patients were taking Vortioxetine in the dose of 10 mg during 6 months. Vortioxetine eliminated both cognitive dysfunction and symptoms of depression in patients of both age groups. Cognitive remission as well as absence of relapses continued within 6 months after medication cancellation. Vortioxetine showed a good acceptability and safety in the study population.